Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Black patients with triple-negative breast cancer may be less likely to receive immunotherapy than white patients
In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower…
Can chatbots help with genetic testing for cancer risk?
A study from Huntsman Cancer Institute at the University of Utah (the U) and NYU…
Common salt activates anti-tumour cells
Sodium chloride, commonly known as “table salt”, was a valuable commodity in history. Today, table…
Targeted delivery of therapeutic RNAs only to cancer, no harm caused to healthy cells
Tel Aviv University’s groundbreaking technology may revolutionise the treatment of cancer and a wide range of diseases and medical conditions.…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.